Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID
Launched by UNIVERSITY OF LOUISVILLE · Mar 17, 2025
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how Osteopathic Manipulative Therapy (OMT) can help people experiencing Long COVID symptoms, which can occur after recovering from COVID-19. While previous research suggested that OMT may improve the sense of smell in some individuals, this study aims to find out if it can also relieve other Long COVID symptoms, such as fatigue, difficulty breathing, and mood changes. Additionally, the trial will compare whether receiving two OMT treatments is more effective than just one.
To participate, individuals must have had a positive COVID-19 test at least six weeks prior and experience at least one Long COVID symptom that affects their daily life. Participants will take digital surveys about their symptoms over eight weeks and receive either the OMT treatment or a placebo (a treatment without active effects) during the study. It's important to note that individuals with certain recent injuries or those currently involved in other Long COVID trials may not be eligible. This trial is currently recruiting participants, and the goal is to better understand the potential benefits of OMT for those suffering from Long COVID.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Individuals must claim they have had a prior positive SARS-CoV-2 test at least 6-weeks before the consenting process to proceed with the study
- * Individuals must claim they have at least one of the following symptoms greater than 6-weeks post infection that is affecting their daily life(these symptoms correlate with the SBQ™-LC):
- Symptoms of Long Covid Inclusion Criteria:
- • Shortness of breath or Difficulty Breathing
- • Difficulty with Movement (balance or tremor)
- • Muscle Pain or stiffness
- • Changes in sexual desire
- • Worsening Generalized Pain
- • Difficulty with Sleep
- • Changes in Mood (anxiety or depression)
- • Changes in Erectile function (Biological males only)
- • Palpations (irregular heart beats)
- • Altered Taste
- • Changes in your Hair
- • Changes in urination
- • Dizziness
- • Altered Smell
- • Changes in Skin
- • Changes in bowels
- • Fatigue
- • Indigestion
- • Dry or irritated eyes
- • Changes in sweating
- • Difficulty with Cognition (memory or thinking)
- • Stomach Pain
- • Changes in menstruation (Biological females only)
- • Chills or shivering
- Exclusion Criteria:
- • If anyone denies they have any of the above symptoms before consent, they will be excluded from the trial
- • They will also be excluded from the trial if they have suffered any fractured bones in the last 3 months (this will further decrease risk to the patient as the patient will be moved by the physician during the treatment protocol)
- • Participants who are enrolled in other Long-COVID trials that have an intervention during their participation in this trial will be excluded. However, if they have a history of enrollment in a long-covid trial that has no interventions during this trial, they will not be excluded based on their history of acquiring experimental treatment.
About University Of Louisville
The University of Louisville is a distinguished academic institution known for its commitment to advancing medical research and clinical innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise to conduct pioneering studies that aim to improve patient outcomes and enhance healthcare practices. With a focus on interdisciplinary collaboration and community engagement, the University of Louisville fosters an environment conducive to groundbreaking research across various medical fields, ensuring adherence to the highest ethical standards and regulatory compliance. Through its clinical trials, the university seeks to translate scientific discoveries into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Louisville, Kentucky, United States
Patients applied
Trial Officials
Darryl Kaelin, MD, Medical Doctorate (US)
Principal Investigator
University of Louisville School of Medicine Chair of PM&R Division of the Department of Neurological Surgery
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported